Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By combining patient-derived functional data with artificial intelligence, our platform provides quantitative insights into ex vivo drug response dynamics.
Every patient is unique, so two patients with the same medical condition may respond differently to the same therapeutic protocol. Precision medicine is an emerging approach for improving the success rate of patient care by identifying the treatment options most likely to be effective for the individual.
What is functional precision medicine?
Functional precision medicine is a strategy in which live patient cells (such as tumor cells) are directly exposed to various drugs in a laboratory to observe their real-time response, providing personalized data to guide the most effective treatment for that specific individual.
Our approach is “functional” because we directly test how effectively anticancer drugs disrupt the normal functioning of a patient's live cancer cells. ImpriMed’s approach to precision oncology is unique in several ways.
Together, these capabilities generate quantitative, data-driven insights that support oncology research, therapeutic hypothesis generation, and data-informed evaluation within precision oncology programs.
How do we get live cancer cells to the lab for testing? This is a real challenge for most companies.
The logistics associated with keeping cells alive long enough to be tested are difficult to overcome. ImpriMed innovated past these challenges by developing a proprietary transport medium that keeps cells healthy during shipping.
Drug sensitivity shows how effectively a drug can kill live cancer cells. Your novel compound can be tested using our test platform to identify the best development plan.
Flow cytometry quantifies the levels of different proteins found on and within tumor cells. This test provides prognostic and diagnostic information.
To determine which drugs elicit a positive clinical response, we conducted an initial study to collect real-world data. We used the data from this clinical study to train AI models so they can predict the ways in which individual patients will respond to a panel of commonly used anticancer drugs. After the initial clinical study, we partner with our amazing network of customers to continuously grow our database of clinical outcomes. These data are added to our existing database and used to further refine the AI models.
Based on our established technology and workflow, we performed clinical studies to evaluate correlation between our predictive value and the actual clinical response to various anticancer drugs.
